TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30496458

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (replacing ethambutol in the standard regimen)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard regimen (including pyrazinamide and rifampicin)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Rifampicin (with peak concentration above 7 mg/L)
Number of subjects: 126
Study: 26305114

Group type: EXPERIMENTAL
Intervention: Additional descriptive information about behaviour corresponding to BPD with explicit mention of BPD as a possible comorbid diagnostic label
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Additional descriptive information about behaviour corresponding to BPD
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: General background information
Number of subjects: 265
Study: 25320199

Group type: EXPERIMENTAL
Intervention: Fusion group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-fusion group
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 22440499

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (3 μg/mm² balloon surface)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Uncoated balloon
Number of subjects: 108
Study: 20350917

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2 mg dexamethasone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone
Number of subjects: 10

Group type: COMPARATOR
Intervention: No dexamethasone (baseline)
Number of subjects: 10
Study: 17470017

Group type: EXPERIMENTAL
Intervention: Periodontal treatment in group 2 (266 patients)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Healthy patients (group 1)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Non-treated group (62 patients dropped out)
Number of subjects: 450
Study: 16001200

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (40 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Misoprostol (200 microg)
Number of subjects: 30
Study: 12067867

Group type: EXPERIMENTAL
Intervention: Lidocaine-bicarbonate bolus (LBB) group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Lidocaine-bicarbonate groups
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 44
Study: 9854159

Group type: EXPERIMENTAL
Intervention: Interferential current (IFC) applied prior to UV treatment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Interferential current (IFC) applied in combination with UV-radiation
Number of subjects: 5

Group type: COMPARATOR
Intervention: Ultraviolet radiation (UV) of 254 nm wavelength
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Interferential current (IFC) applied after UV treatment
Number of subjects: 5
Study: 7875472

Group type: EXPERIMENTAL
Intervention: midazolam (35 micrograms/kg) and lidocaine spray (100 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: midazolam and placebo lidocaine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: placebo midazolam and lidocaine
Number of subjects: 200

Group type: COMPARATOR
Intervention: placebo midazolam and placebo lidocaine
Number of subjects: 200
Study: 2484856

Group type: EXPERIMENTAL
Intervention: N-acetylprocainamide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Quinidine plus digoxin
Number of subjects: 18
Study: 213498

Group type: EXPERIMENTAL
Intervention: CP-20,961 administered prior to challenge
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CP-20,961 administered 24 hours after challenge
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CP-20,961 administered 48 hours after challenge
Number of subjects: 60
Study: 30145342

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 18
Study: 28701225

Group type: EXPERIMENTAL
Intervention: D-cycloserine 50 mg/day
Number of subjects: 41
Study: 25322869

Group type: EXPERIMENTAL
Intervention: Ear acupressure
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (routine activities)
Number of subjects: 120
Study: 23395191

Group type: EXPERIMENTAL
Intervention: Psychosocial skills training and health management program (Helping Older People Experience Success)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 183
Study: 20800453

Group type: EXPERIMENTAL
Intervention: 6-months vocational rehabilitation program
Number of subjects: 112

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 112
Study: 19154828

Group type: EXPERIMENTAL
Intervention: 3.0 hours of interdisciplinary rehabilitation a week
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 4.5 hours of interdisciplinary rehabilitation a week
Number of subjects: 108

Group type: COMPARATOR
Intervention: No active rehabilitation
Number of subjects: 108
Study: 17763317

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 127
Study: 15754991

Group type: EXPERIMENTAL
Intervention: Robust anisotropic Gaussian fitting for volumetric characterization of pulmonary nodules
Number of subjects: 1310

Group type: COMPARATOR
Intervention: Gamma-normalized Laplacian approach (Linderberg, 1998)
Number of subjects: 1310

Group type: COMPARATOR
Intervention: Standard sample estimation approach (Matei, 2001)
Number of subjects: 1310
Study: 11809990

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) at 12 (3) cm H2O for 40 minutes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV) with flow assist 4.9 (1.3) cm H2O/l.s and volume assist 18.9 (5.1) cm H2O/l for 40 minutes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of PAV and PSV
Number of subjects: 12
Study: 10206300

Group type: EXPERIMENTAL
Intervention: Gelatinase-A in glioma specimens
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Gelatinase-B transcript and activity levels
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: MT1-MMP mRNA levels
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Gelatinase-B expression
Number of subjects: 53
Study: 8719441

Group type: EXPERIMENTAL
Intervention: Gn-RHa plus hGH therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gn-RHa alone (control group)
Number of subjects: 30
Study: 2624987

Group type: EXPERIMENTAL
Intervention: Angong‐Niuhuang Pills (ANP)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Other medical treatment (Control)
Number of subjects: 104
Study: 772973

Group type: EXPERIMENTAL
Intervention: Digilanid C
Number of subjects: 66

Group type: COMPARATOR
Intervention: Isolanid (Richter)
Number of subjects: 66
Study: 31025363

Group type: EXPERIMENTAL
Intervention: Grass AIT
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Birch AIT
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Targeted treatment
Number of subjects: 95

Group type: COMPARATOR
Intervention: Untargeted treatments
Number of subjects: 95
Study: 27558412

Group type: EXPERIMENTAL
Intervention: Total Hip Replacement (THR) with greater widespread hyperalgesia and more severe OA (Grade 4 OA)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR) with greater widespread hyperalgesia and less severe OA (Grade 3 OA)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Total Knee Replacement (TKR) with more severe OA (Grade 4 OA)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Total Hip Replacement (THR) with more severe OA (Grade 4 OA)
Number of subjects: 473
Study: 25284616

Group type: EXPERIMENTAL
Intervention: Development of portal vein thrombosis (PVT)
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Baseline esophageal varices
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Prothrombin time
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Disease progression
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Prior development of PVT
Number of subjects: 1243
Study: 23161357

Group type: COMPARATOR
Intervention: bupivacaine 0.25% (1 ml kg(‐1); Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bupivacaine plus dexmedetomidine (1 μg kg(‐1); Group BD)
Number of subjects: 60
Study: 21810198

Group type: EXPERIMENTAL
Intervention: Intervention group discussed self-efficacy scores using the Long-Term Medication Behaviour Self-Efficacy Scale (LTMBSES)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group did not discuss self-efficacy scores
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Patients ≤ 55 years
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Patients > 55 years
Number of subjects: 54
Study: 19476183

Group type: EXPERIMENTAL
Intervention: Modified transtibial technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accessory medial portal technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retrograde drilling technique
Number of subjects: 0
Study: 15564698

Group type: EXPERIMENTAL
Intervention: Sauna treatment (daily 60 degrees C far infrared‐ray dry sauna for 15 min, followed by 30 min bed rest with blankets, for 5 days per week for 2 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sauna treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-treated group (bed rest in a temperature‐controlled room at 24 degrees C for 45 min)
Number of subjects: 30
Study: 10626311

Group type: EXPERIMENTAL
Intervention: Experimental booklet (The Back Book)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Traditional booklet
Number of subjects: 162
Study: 7717598

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (160 mg-800 mg orally twice a day on a thrice weekly regimen)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Dapsone-pyrimethamine (100 mg of dapsone plus 50 mg of pyrimethamine orally twice weekly)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 230

Group type: COMPARATOR
Intervention: Dapsone-pyrimethamine
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 230
Study: 2288407

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg famotidine
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg famotidine
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg famotidine
Number of subjects: 107

Group type: COMPARATOR
Intervention: No famotidine (control group)
Number of subjects: 107
Study: 7225272

Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neuroleptanalgesia
Number of subjects: 20
Study: 30900916

Group type: EXPERIMENTAL
Intervention: 70 kVp CT with 60 mL of CM
Number of subjects: 80

Group type: COMPARATOR
Intervention: 120 kVp CT with 100 mL of CM
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (70 kVp and 120 kVp)
Number of subjects: 80
Study: 29054980

Group type: EXPERIMENTAL
Intervention: Enhanced Milieu Teaching (EMT) intervention with parent training
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual community treatments
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Post hoc analysis of children with receptive-expressive language delays
Number of subjects: 97
Study: 27863271

Group type: EXPERIMENTAL
Intervention: Combined hormonal vaginal ring (15mcg ethinyl estradiol and 120mcg etonogestrel per day for 84 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combined hormonal oral pill (30mcg ethinyl estradiol and 150mcg levonorgestrel for 84 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined hormonal vaginal ring
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combined hormonal oral pill
Number of subjects: 60
Study: 24696010

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate, 0.05%, ointment applied once daily for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: UV‐A1 phototherapy (50 J/cm²) performed 4 times weekly for 3 months
Number of subjects: 30
Study: 22978309

Group type: EXPERIMENTAL
Intervention: Cineole (200 mg, three times per day for 6 months)
Number of subjects: 247
Study: 19274793

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition with multivitamins (MVP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition exposed to light
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition with trace elements (TEs)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (all groups)
Number of subjects: 80
Study: 17525141

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (blood glucose >8 mmol/l) in lacunar stroke
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (blood glucose >8 mmol/l) in non-lacunar stroke
Number of subjects: 1375
Study: 15249353

Group type: EXPERIMENTAL
Intervention: Myocardial Infarction (MI) only
Number of subjects: 9434

Group type: COMPARATOR
Intervention: Diabetes only
Number of subjects: 9434
Study: 11642426

Group type: EXPERIMENTAL
Intervention: Glottic reconstruction with false vocal fold (FVF) mucosal flap
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard frontolateral partial laryngectomy (FLPL) without glottic reconstruction
Number of subjects: 0
Study: 11907944

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol delivery system A (twice a week)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol delivery system B (once a week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both systems (A and B)
Number of subjects: 20
Study: 8023719

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg o.m.)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Histamine H2-receptor antagonists (cimetidine 400 mg q.d.s. or ranitidine 150 mg b.d.)
Number of subjects: 448
Study: 31880055

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 37% carbamide peroxide (CP)
Number of subjects: 50
Study: 29042091

Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RDN)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 58
Study: 27183546

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide (FAc) implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2 µg/day FAc
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication, trabeculoplasty, or surgery
Number of subjects: 0
Study: 25625612

Group type: EXPERIMENTAL
Intervention: CO2 with balanced propofol sedation (BPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Air with balanced propofol sedation (BPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Air with propofol + opioid sedation (PS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CO2 with propofol + opioid sedation (PS)
Number of subjects: 0
Study: 23395927

Group type: EXPERIMENTAL
Intervention: Robotic-assisted total laparoscopic hysterectomy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Laparoscopic hysterectomy
Number of subjects: 53
Study: 19631970

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 53
Study: 19269130

Group type: EXPERIMENTAL
Intervention: Vaccine Safety Messages (VSM)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Vaccine Information Statement (VIS)
Number of subjects: 108
Study: 17291166

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Somatic relaxation training
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 83
Study: 15064512

Group type: EXPERIMENTAL
Intervention: Experimental method using a 2.0 X magnifying lens mounted on a headband
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional method of catheter insertion
Number of subjects: 44
Study: 11593077

Group type: EXPERIMENTAL
Intervention: 600 mg of mifepristone
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 9455695

Group type: EXPERIMENTAL
Intervention: Vitamin E (2 x 400 IU RRR‐alpha‐tocopherol/day) for 12 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Vitamin E retreatment after cessation
Number of subjects: 23
Study: 7947424

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms with morphine 0.25 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sufentanil 10 micrograms with morphine 0.25 mg
Number of subjects: 30
Study: 2452245

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 134

Group type: COMPARATOR
Intervention: Ampicillin or Chloramphenicol
Number of subjects: 134
Study: 30074402

Group type: EXPERIMENTAL
Intervention: Load of 4.5 kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Load of 9.0 kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Load of 13.5 kg
Number of subjects: 11
Study: 27130868

Group type: EXPERIMENTAL
Intervention: Belatacept MI
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Belatacept LI
Number of subjects: 359

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 359

Group type: COMPARATOR
Intervention: Belatacept and Cyclosporine
Number of subjects: 359
Study: 26155841

Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment navigators
Number of subjects: 40
Study: 24011635

Group type: EXPERIMENTAL
Intervention: Test drug (newly developed lamivudine tablet)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Reference drug (branded lamivudine tablet)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 28
Study: 21119152

Group type: EXPERIMENTAL
Intervention: Home treatment model
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional psychiatric out-patient care
Number of subjects: 60
Study: 18480202

Group type: EXPERIMENTAL
Intervention: efavirenz plus two NRTIs
Number of subjects: 757

Group type: COMPARATOR
Intervention: lopinavir-ritonavir plus two NRTIs
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: lopinavir-ritonavir plus efavirenz (NRTI-sparing group)
Number of subjects: 757
Study: 15898289

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate lotion
Number of subjects: 229

Group type: COMPARATOR
Intervention: Clobetasol propionate emollient cream
Number of subjects: 229

Group type: COMPARATOR
Intervention: Lotion vehicle
Number of subjects: 229
Study: 12926095

Group type: EXPERIMENTAL
Intervention: Exemestane (EXE)
Number of subjects: 769

Group type: COMPARATOR
Intervention: Megestrol Acetate (MA)
Number of subjects: 769
Study: 10821298

Group type: EXPERIMENTAL
Intervention: Low-dose oral oestrogen (1 mg, 17-beta-estradiol)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oestrogen (1 mg 17-beta-estradiol) in combination with low-dose (0.5 mg) continuous norethisterone acetate (NETA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (Low-dose oral oestrogen)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (Oestrogen with NETA)
Number of subjects: 34
Study: 9007160

Group type: EXPERIMENTAL
Intervention: Acyclovir (dose-dependent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy donors (control)
Number of subjects: 0
Study: 1387445

Group type: EXPERIMENTAL
Intervention: Sodium citrate
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sodium citrate/ranitidine
Number of subjects: 2
Study: 6573807

Group type: EXPERIMENTAL
Intervention: Intra-amniotic prostaglandin F2 alpha
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravaginal prostaglandin E2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both prostaglandin F2 alpha and E2
Number of subjects: 0
Study: 31410633

Group type: EXPERIMENTAL
Intervention: Contezolid (MRX-I) at therapeutic doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concentration-QT model
Number of subjects: 0
Study: 29634661

Group type: EXPERIMENTAL
Intervention: Early ART initiation (N=408)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Delayed ART initiation (N=408)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Systolic pressure >140mmHg at enrolment
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Systolic pressure <90mmHg at enrolment
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Prevalent and incident hypertension
Number of subjects: 816
Study: 26359184

Group type: EXPERIMENTAL
Intervention: 40 min of moderate physical activity every school day (intervention)
Number of subjects: 3534

Group type: COMPARATOR
Intervention: Swedish standard curriculum of 60 min of physical activity per school week (control)
Number of subjects: 3534
Study: 24666591

Group type: EXPERIMENTAL
Intervention: Multi-component multidisciplinary collaborative intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study: 22361211

Group type: EXPERIMENTAL
Intervention: Tailored postal feedback on prescribing of acamprosate
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Tailored postal feedback on prescribing of naltrexone
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Tailored postal feedback intervention
Number of subjects: 115
Study: 19505812

Group type: EXPERIMENTAL
Intervention: Dietary supplementation of docosahexaenoic acid (DHA) at levels close to 0.32%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary supplementation of arachidonic acid (ARA) at levels of at least 0.3%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulas providing close to the worldwide human milk mean of 0.32% DHA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (formula-fed infants without DHA and ARA supplementation)
Number of subjects: 0
Study: 18065583

Group type: EXPERIMENTAL
Intervention: 20 microg/d (800 IU/d) vitamin D(3)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: 50 microg/d (2000 IU/d) vitamin D(3)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Algorithm for prescribing vitamin D
Number of subjects: 208
Study: 15110729

Group type: EXPERIMENTAL
Intervention: Visually spoken words (video of a talker's utterance without audio)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual speech primes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetition priming effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming found in all tasks
Number of subjects: 0
Study: 11214131

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUS
Number of subjects: 236

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 236